AU2022215580A1 - Formulation of furin inhibitor for inhalation - Google Patents

Formulation of furin inhibitor for inhalation Download PDF

Info

Publication number
AU2022215580A1
AU2022215580A1 AU2022215580A AU2022215580A AU2022215580A1 AU 2022215580 A1 AU2022215580 A1 AU 2022215580A1 AU 2022215580 A AU2022215580 A AU 2022215580A AU 2022215580 A AU2022215580 A AU 2022215580A AU 2022215580 A1 AU2022215580 A1 AU 2022215580A1
Authority
AU
Australia
Prior art keywords
type
freeform
pharmaceutical composition
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022215580A
Other languages
English (en)
Other versions
AU2022215580A9 (en
Inventor
Sheng CUI
Dinesh Shyamdeo Mishra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BP Asset V Inc
Original Assignee
BP Asset V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BP Asset V Inc filed Critical BP Asset V Inc
Publication of AU2022215580A1 publication Critical patent/AU2022215580A1/en
Publication of AU2022215580A9 publication Critical patent/AU2022215580A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022215580A 2021-02-03 2022-02-03 Formulation of furin inhibitor for inhalation Abandoned AU2022215580A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145363P 2021-02-03 2021-02-03
US63/145,363 2021-02-03
PCT/US2022/015098 WO2022169962A1 (en) 2021-02-03 2022-02-03 Formulation of furin inhibitor for inhalation

Publications (2)

Publication Number Publication Date
AU2022215580A1 true AU2022215580A1 (en) 2023-08-10
AU2022215580A9 AU2022215580A9 (en) 2024-05-09

Family

ID=80446118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022215580A Abandoned AU2022215580A1 (en) 2021-02-03 2022-02-03 Formulation of furin inhibitor for inhalation

Country Status (9)

Country Link
US (1) US20240307374A1 (https=)
EP (1) EP4288052A1 (https=)
JP (1) JP2024506291A (https=)
KR (1) KR20230142752A (https=)
CN (1) CN117222410A (https=)
AU (1) AU2022215580A1 (https=)
CA (1) CA3205921A1 (https=)
IL (1) IL304858A (https=)
WO (1) WO2022169962A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
DK2400950T3 (da) * 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
PT3357919T (pt) * 2014-02-14 2020-02-20 Respivert Ltd Compostos heterocíclicos aromáticos como compostos antiinflamatórios
BR112020022961A2 (pt) 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina

Also Published As

Publication number Publication date
CA3205921A1 (en) 2022-08-11
KR20230142752A (ko) 2023-10-11
EP4288052A1 (en) 2023-12-13
IL304858A (en) 2023-10-01
JP2024506291A (ja) 2024-02-13
WO2022169962A1 (en) 2022-08-11
US20240307374A1 (en) 2024-09-19
AU2022215580A9 (en) 2024-05-09
CN117222410A (zh) 2023-12-12

Similar Documents

Publication Publication Date Title
TWI800567B (zh) 包含血漿激肽釋放酶抑制劑之劑型
EP3856164B1 (en) Morphic forms of complement factor d inhibitors
US10550119B2 (en) Dihydroindolizinone derivative
US11773078B2 (en) Furin inhibitors
EP4149470A1 (en) Pharmaceutical formulations and uses thereof
JP2017530175A (ja) 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
CN113645954B (zh) 含有苯并氮杂卓化合物的冻干组合物
PT2321286E (pt) Derivados de n-óxido de pirazina substituídos
US20240307374A1 (en) Formulation of furin inhibitor for inhalation
BR112021014956A2 (pt) Composições e compostos terapêuticos
CN103561723B (zh) 具有改善稳定性的奥米沙班制剂
BR112021008462A2 (pt) compostos e composições terapêuticas
RS63069B1 (sr) Dozni oblici koji sadrže inhibitor kalikreina plazme
RU2536425C2 (ru) Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
CN104650058A (zh) 利伐沙班一水合物化合物
IL303227B2 (en) Combined pumped storage power plant - desalination plant on the beach (ocean), or river, or lake
HK40050068B (zh) 含有托格列净的固体制剂及其生产方法
TWI551289B (zh) 具有改良之安定性之奧米沙班調配物
HK40025124B (zh) 注射用组合物
Wang Novel Delivery Systems for Nasal Adminstration of Anthrax Vaccine
TW200403064A (en) Pharmaceutical composition for injection of cefem compound

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period